Emgality ® (galcanezumab-gnlm) injection

100 mg/mL, 120 mg/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

EMGALITY® (galcanezumab-gnlm): Dosage and Administration

The migraine prevention dose is 120 mg once monthly, with a 240 mg loading dose as the initial dose. The episodic cluster headache dose is 300 mg at the onset of the cluster period, and then monthly until the end of the cluster period.

Migraine Prevention Dosing

The recommended dose is 120-mg injected subcutaneously once monthly, following an initial 240-mg loading loading dose (administered as 2 consecutive injections of 120 mg each).1

Episodic Cluster Headache Dosing

The recommended dose is 300 mg, 3 consecutive injections of 100 mg each, injected subcutaneously monthly throughout a cluster period.1

Method of Administration

Galcanezumab is for subcutaneous administration.1 A patient may self-inject by following the instructions for use.

Sites for injection include the

  • abdomen

  • thigh

  • back of the upper arm, and

  • buttocks.1

Enclosed Prescribing Information

EMGALITY® (galcanezumab-gnlm) injection, for subcutaneous use, Lilly

References

1. Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.

Date of Last Review: April 30, 2019

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Ask us a question Chat with us

Submit a Request

Visit Us @LillyMedical